Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. A Translational Research Success Story.

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 1-49

  McDaniel, Russell E ^a   Maximov, Philipp Y ^a   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Aromatase inhibitors; Chemoprevention; Estrogen induced apoptosis; Raloxifene; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

EID: 84880311905     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00007-1     Document Type: Chapter

References (230)

1. Allen E., Doisey E.A. An ovarian hormone: Preliminary reports on its localization, extraction and partial purification and action in test animals. Journal of the American Medical Association 1923, 81(10):819-821.
2. Anderson G.L., Chlebowski R.T., Aragaki A.K., Kuller L.H., Manson J.E., Gass M., et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. The Lancet Oncology 2012, 13(5):476-486.
3. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2004, 291(14):1701-1712.
4. Ariazi E.A., Cunliffe H.E., Lewis-Wambi J.S., Slifker M.J., Willis A.L., Ramos P., et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(47):18879-18886.
5. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. Journal of Clinical Oncology 2012, 30(22):2718-2724.
6. Bain R.R., Jordan V.C. Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy. Biochemical Pharmacology 1983, 32(2):373-375.
7. Balaburski G.M., Dardes R.C., Johnson M., Haddad B., Zhu F., Ross E.A., et al. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: A unifying concept in anti-hormone resistance. International Journal of Oncology 2010, 37(2):387-398.
8. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England Journal of Medicine 2012, 366(6):520-529.
9. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 2009, 27(16):2630-2637.
10. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. The Lancet 2002, 359(9324):2131-2139.
11. Baumler E. Paul Ehrlich: Scientist for life 1984, Holmes & Meier Publishers, New York. 1st ed.
12. Beall P.T., Misra K.L., Young R.L., Spjut H.J., Evan H.J., LeBlanc A. Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcified Tissue International 1985, 36:123-125.
13. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. The Lancet 1896, 148:104-107.
14. Bergh J., Jonsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattstrom D., et al. FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. Journal of Clinical Oncology 2012, 30(16):1919-1925.
15. Berthois Y., Katzenellenbogen J.A., Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(8):2496-2500.
16. Bindal R.D., Carlson K.E., Katzenellenbogen B.S., Katzenellenbogen J.A. Lipophilic impurities, not phenolsulfonaphthalein, account for the estrogenic activity in commercial preparations of phenol red. Journal of Steroid Biochemistry 1988, 31(3):287-293.
17. Bindal R.D., Katzenellenbogen J.A. Bis(4-hydroxyphenyl)[2-(phenoxysulfonyl)phenyl]methane: Isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein). Journal of Medicinal Chemistry 1988, 31(10):1978-1983.
18. Black L.J., Jones C.D., Falcone J.F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sciences 1983, 32(9):1031-1036.
19. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. Journal of Clinical Oncology 2005, 23(22):5138-5147.
20. Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. The New England Journal of Medicine 1976, 294(8):405-410.
21. Boyd S. On oophorectomy in cancer of the breast. British Medical Journal 1900, 2:1161-1167.
22. Brauch H., Schroth W., Goetz M.P., Mürdter T.E., Winter S., Ingle J.N., et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. Journal of Clinical Oncology 2013, 31:176-180.
23. Breast Cancer Facts and Figures (2011-2012). Atlanta, American Cancer Society: American Cancer Society, Inc.
24. Breast Cancer Survival Rates by Stage (2011). American Cancer Society.
25. Brodie A.M., Longcope C. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione. Endocrinology 1980, 106(1):19-21.
26. Brodie A.M., Marsh D., Brodie H.J. Aromatase inhibitors. IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione. Journal of Steroid Biochemistry 1979, 10(4):423-429.
27. Brodie A.M., Schwarzel W.C., Shaikh A.A., Brodie H.J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 1977, 100(6):1684-1695.
28. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389(6652):753-758.
29. Canadian Cancer Statistics (2012). Canadian Cancer Society.
30. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. Journal of the American Medical Association 2003, 289(24):3243-3253.
31. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. Journal of Clinical Oncology 2007, 25(5):486-492.
32. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British Journal of Cancer 1971, 25(2):270-275.
33. Consensus conference Adjuvant chemotherapy for breast cancer. Journal of the American Medical Association 1985, 254(24):3461-3463.
34. Coombes R.C., Goss P., Dowsett M., Gazet J.C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. The Lancet 1984, 2(8414):1237-1239.
35. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The New England Journal of Medicine 2004, 350(11):1081-1092.
36. Cooper R.G. Combination chemotherapy in hormone resistant breast cancer. Proceeding of the American Association for Cancer Research 1969, 10:15.
37. Crandall C.J., Aragaki A.K., Cauley J.A., McTiernan A., Manson J.E., Anderson G., et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Research and Treatment 2012, 132(1):275-285.
38. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Journal of the American Medical Association 1999, 281(23):2189-2197.
39. Cummings S.R., Ensrud K., Delmas P.D., LaCroix A.Z., Vukicevic S., Reid D.M., et al. Lasofoxifene in postmenopausal women with osteoporosis. The New England Journal of Medicine 2010, 362(8):686-696.
40. Cuzick J., Baum M. Tamoxifen and contralateral breast cancer. The Lancet 1985, 2(8449):282.
41. Cuzick J., Forbes J.F., Howell A. Re: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 2006, 98(9):643. author reply 643-644.
42. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet 2011, 378(9793):771-784.
43. DeGregorio M.W., Wurz G.T., Taras T.L., Erkkola R.U., Halonen K.H., Huupponen R.K. Pharmacokinetics of (deaminohydroxy)toremifene in humans: A new, selective estrogen-receptor modulator. European Journal of Clinical Pharmacology 2000, 56(6-7):469-475.
44. Delarue F., Kedjouar B., Mesange F., Bayard F., Faye J.C., Poirot M. Modifications of benzylphenoxy ethanamine antiestrogen molecules: Influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity. Biochemical Pharmacology 1999, 57(6):657-661.
45. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology 2010, 28(30):4594-4600.
46. Dieudonne A.S., Lambrechts D., Claes B., Vandorpe T., Wildiers H., Timmerman D., et al. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: Response and biomarkers in tamoxifen users. Breast Cancer Research and Treatment 2009, 118(3):531-538.
47. Dodds E. Biological effects of the synthetic oestrogenic substance 4:4'-dihydroxy-alpha:beta-diethylstilbene. The Lancet 1938, 232(6015):1389-1391.
48. Dodds E.C., Goldberg L., Lawson W., Robinson R. Oestrogenic activity of esters of diethyl stilboestrol. Nature 1938, 142(3587):211-212.
49. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology 2010, 28(3):509-518.
50. EBCTCG Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialisits' Collaborative Group. The Lancet 1998, 351(9114):1451-1467.
51. EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. The Lancet 2005, 365(9472):1687-1717.
52. EISRCM O Câncer de Mama no Brasil Situacão epidemiológica e rastreamento 2006, Encontro Internacional Sobre Rastreamento de Cancer de Mama, Rio de Janeiro.
53. Ellis M.J., Gao F., Dehdashti F., Jeffe D.B., Marcom P.K., Carey L.A., et al. Lower-dose vs. high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. Journal of the American Medical Association 2009, 302(7):774-780.
54. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Journal of the American Medical Association 1999, 282(7):637-645.
55. Fan P., Jordan V.C. An emerging principle: Selective nuclear receptor modulators. Estrogen actions, SERMs, and women's health 2013, Imperial College Press, London. V.C. Jordan (Ed.).
56. Fan P., McDaniel R.E., Kim H.R., Clagett D., Haddad B., Jordan V.C. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. European Journal of Cancer 2012, 48:3488-3498.
57. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2010, 46:765-781.
58. Fisher B., Carbone P., Economou S.G., Frelick R., Glass A., Lerner H., et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. The New England Journal of Medicine 1975, 292(3):117-122.
59. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. The New England Journal of Medicine 1989, 320(8):479-484.
60. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 2005, 97(22):1652-1662.
61. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998, 90(18):1371-1388.
62. Folca P.J., Glascock R.F., Irvine W.T. Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy. The Lancet 1961, 2(7206):796-798.
63. Fornander T., Rutqvist L.E., Cedermark B., Glas U., Mattsson A., Silfversward C., et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. The Lancet 1989, 1(8630):117-120.
64. Furr B.J., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacology and Therapeutics 1984, 25(2):127-205.
65. Glascock R.F., Hoekstra W.G. Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep. The Biochemical Journal 1959, 72:673-682.
66. Goss P.E., Ingle J.N., Ales-Martinez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., et al. Exemestane for breast-cancer prevention in postmenopausal women. The New England Journal of Medicine 2011, 364(25):2381-2391.
67. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. The New England Journal of Medicine 2003, 349(19):1793-1802.
68. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 2005, 97(17):1262-1271.
69. Gottardis M.M., Jiang S.Y., Jeng M.H., Jordan V.C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Research 1989, 49(15):4090-4093.
70. Gottardis M.M., Jordan V.C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Research 1987, 47(15):4020-4024.
71. Gottardis M.M., Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 1988, 48(18):5183-5187.
72. Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., Jordan V.C. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Research 1990, 50(11):3189-3192.
73. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 1988, 48(4):812-815.
74. Gottardis M.M., Wagner R.J., Borden E.C., Jordan V.C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Research 1989, 49(17):4765-4769.
75. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Research 1993, 53(17):3919-3924.
76. Gruber C., Gruber D. Bazedoxifene (Wyeth). Current Opinion in Investigational Drugs 2004, 5(10):1086-1093.
77. Haddow A. David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer 1970, 26(4):737-754.
78. Haddow A., Watkinson J.M., Paterson E., Koller P.C. Influence of synthetic oestrogens on advanced malignant disease. British Medical Journal 1944, 2(4368):393-398.
79. Hard G.C., Latropoulos M.J., Jordan K., Radi L., Kaltenberg O.P., Imondi A.R., et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Research 1993, 53(19):4534-4541.
80. Harper M.J., Walpole A.L. Mode of action of I.C.I. 46,474 in preventing implantation in rats. The Journal of Endocrinology 1967, 37(1):83-92.
81. Harper M.J., Walpole A.L. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. Journal of Reproduction and Fertility 1967, 13(1):101-119.
82. Hecker E., Vegh I., Levy C.M., Magin C.A., Martinez J.C., Loureiro J., et al. Clinical trial of clomiphene in advanced breast cancer. European Journal of Cancer 1974, 10(11):747-749.
83. Herman M.E., Katzenellenbogen B.S. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Research 1994, 54(22):5867-5874.
84. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. The Lancet 2005, 365(9453):60-62.
85. Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. Journal of Clinical Oncology 2004, 22(9):1605-1613.
86. Howlader N., Noone A.M., Krapcho M., Neyman N., Aminou R., Altekruse S.F., et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations) 2009, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/.
87. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
88. Hu Z.Z., Kagan B.L., Ariazi E.A., Rosenthal D.S., Zhang L., Li J.V., et al. Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One 2011, 6(6):e20410.
89. Huggins C., Grand L.C., Brillantes F.P. Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 1961, 189:204-207.
90. INCA A Situacao do Cancer no Brasil 2006, Instituto Nacional de Cancer, Rio de Janeiro.
91. Ingle J.N., Ahmann D.L., Green S.J., Edmonson J.H., Bisel H.F., Kvols L.K., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. The New England Journal of Medicine 1981, 304(1):16-21.
92. Jain N., Kanojia R.M., Xu J., Jian-Zhong G., Pacia E., Lai M.T., et al. Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness. Journal of Medicinal Chemistry 2006, 49(11):3056-3059.
93. Jain N., Xu J., Kanojia R.M., Du F., Jian-Zhong G., Pacia E., et al. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms. Journal of Medicinal Chemistry 2009, 52(23):7544-7569.
94. Jensen E.V., Jacobson H.I. Basic guides to the mechanism of estrogen action. Recent Progress in Hormone Resistence 1962, 18:387-414.
95. Jiang S.Y., Wolf D.M., Yingling J.M., Chang C., Jordan V.C. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Molecular and Cellular Endocrinology 1992, 90(1):77-86.
96. Jordan V.C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. European Journal of Cancer 1976, 12(6):419-424.
97. Jordan V.C. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Reviews on Endocrine-Related Cancer 1978, (October Suppl.):49-55.
98. Jordan V.C. Biochemical pharmacology of antiestrogen action. Pharmacological Reviews 1984, 36(4):245-276.
99. Jordan V.C. Chemotherapy is antihormonal therapy-how much proof doOncologists need?. European Journal of Cancer 1998, 34(5):606-608.
100. Jordan V.C. Selective estrogen receptor modulation: A personal perspective. Cancer Research 2001, 61(15):5683-5687.
101. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. Journal of Medicinal Chemistry 2003, 46(6):883-908.
102. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. Journal of Medicinal Chemistry 2003, 46(7):1081-1111.
103. Jordan V.C. Tamoxifen: A most unlikely pioneering medicine. Nature Reviews. Drug Discovery 2003, 2(3):205-213.
104. Jordan V.C. Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 2004, 5(3):207-213.
105. Jordan V.C. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology 2006, 147(Suppl. 1):S269-S276.
106. Jordan V.C. The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer-Survival or death?. Journal of Clinical Oncology 2008, 26(18):3073-3082.
107. Jordan V.C. Tamoxifen: Catalyst for the change to targeted therapy. European Journal of Cancer 2008, 44(1):30-38.
108. Jordan V.C., Allen K.E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. European Journal of Cancer 1980, 16(2):239-251.
109. Jordan V.C., Allen K.E., Dix C.J. Pharmacology of tamoxifen in laboratory animals. Cancer Treatment Reports 1980, 64(6-7):745-759.
110. Jordan V.C., Bain R.R., Brown R.R., Gosden B., Santos M.A. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Research 1983, 43(3):1446-1450.
111. Jordan V.C., Collins M.M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. The Journal of Endocrinology 1977, 75(2):305-316.
112. Jordan V.C., Dix C.J., Allen K.E. The effectiveness of longterm treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant therapy of cancer II 1979, 19-26. Grune and Stratton, New York. S.E. Salmone, S.E. Jones (Eds.).
113. Jordan V.C., Dix C.J., Naylor K.E., Prestwich G., Rowsby L. Nonsteroidal antiestrogens: Their biological effects and potential mechanisms of action. Journal of Toxicology and Environmental Health 1978, 4(2-3):363-390.
114. Jordan V.C., Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. European Journal of Cancer 1975, 11(3):205-206.
115. Jordan V.C., Liu H., Dardes R. Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: Sex steroids as mediators of both cell proliferation and cell death. Journal of the National Cancer Institute 2002, 94(15):1173. author reply 1173-1175.
116. Jordan V.C., Mittal S., Gosden B., Koch R., Lieberman M.E. Structure-activity relationships of estrogens. Environmental Health Perspectives 1985, 61:97-110.
117. Jordan V.C., Naylor K.E., Dix C.J., Prestwich G. Anti-oestrogen action in experimental breast cancer. Recent Results in Cancer Research 1980, 71:30-44.
118. Jordan V.C., Phelps E., Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment 1987, 10(1):31-35.
119. Jordan V.C., Robinson S.P. Species-specific pharmacology of antiestrogens: Role of metabolism. Federation Proceedings 1987, 46(5):1870-1874.
120. Jordan V.C., Schafer J.M., Levenson A.S., Liu H., Pease K.M., Simons L.A., et al. Molecular classification of estrogens. Cancer Research 2001, 61(18):6619-6623.
121. Jordan V.C., Wolf M., Mirecki D.M., Whitford D., Welshons W.V. Hormone receptor assays: Clinical usefulness in the management of carcinoma of the breast. CRC Critical Reviews in Clinical Laboratory Sciences 1988, 26:97-152.
122. Kagan R., Williams R.S., Pan K., Mirkin S., Pickar J.H. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010, 17(2):281-289.
123. Katzenellenbogen B.S., Kendra K.L., Norman M.J., Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Research 1987, 47(16):4355-4360.
124. Kawate H., Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clinical Interventions in Aging 2011, 6:151-160.
125. Kennedy B.J. Hormone therapy for advanced breast cancer. Cancer 1965, 18(12):1551-1557.
126. Kennedy B.J. Systemic effects of androgenic and estrogenic hormones in advanced breast cancer. Journal of the American Geriatrics Society 1965, 13:230-235.
127. Kennedy B.J., Nathanson I.T. Effect of intensive sex steroid hormone therapy in advanced breast cancer. Journal of the American Medical Association 1953, 152:1135-1141.
128. Kiyotani K., Mushiroda T., Imamura C.K., Hosono N., Tsunoda T., Kubo M., et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Journal of Clinical Oncology 2010, 28(8):1287-1293.
129. Klopper A., Hall M. New synthetic agent for the induction of ovulation: Preliminary trials in women. British Medical Journal 1971, 1(5741):152-154.
130. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., Lyttle C.R. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 2005, 146(9):3999-4008.
131. Lacassagne A. Influence d'un facteur familial dans la production par la folliculine, de cancers mammaires chez la souris male. Comptes Rendus des Seances de la Societe de Biologie et des ses Filiales (Paris) 1933, 114:427-429.
132. Lacassagne A. A comparative study of the carcinogenic action of certain oestrogenic hormones. American Journal of Cancer 1936, 28:735-740.
133. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. American Journal of Cancer 1936, 27(2):217-228.
134. LaCroix A.Z., Chlebowski R.T., Manson J.E., Aragaki A.K., Johnson K.C., Martin L., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. Journal of the American Medical Association 2011, 305(13):1305-1314.
135. Lammers L.A., Mathijssen R.H., van Gelder T., Bijl M.J., de Graan A.J., Seynaeve C., et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. British Journal of Cancer 2010, 103(6):765-771.
136. Lash T.L., Cronin-Fenton D., Ahern T.P., Rosenberg C.L., Lunetta K.L., Silliman R.A., et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. Journal of the National Cancer Institute 2011, 103(6):489-500.
137. Lathrop A.E., Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. Journal of Cancer Research 1916, 1(1):1-19.
138. Laughlin R.C., Carey T.F. Cataracts in patients treated with triparanol. Journal of the American Medical Association 1962, 181:369-370.
139. LBCSG Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. The Lancet 1984, 1(8384):1256-1260.
140. Lednicer D., Emmert D.E., Duncan G.W., Lyster S.C. Mammalian antifertility agents. V. 5,6-Diarylhodronaphtalenes. Journal of Medicinal Chemistry 1967, 10(6):1051-1054.
141. Lednicer D., Lyster S.C., Duncan G.W. Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. Journal of Medicinal Chemistry 1967, 10(1):78-84.
142. Legha S.S., Slavik M., Carter S.K. Nafoxidine-An antiestrogen for the treatment of breast cancer. Cancer 1976, 38(4):1535-1541.
143. Lerner L.J. The first nonsteroidal antiestrogen-MER25. Nonsteroidal antiestrogens, molecular pharmacology and antitumor activity 1981, 1-16. Academic Press, Sydney. R.L. Sutherland, V.C. Jordan (Eds.).
144. Lerner L.J., Holthaus F.J., Thompson C.R. A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 1958, 63(3):295-318.
145. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Research 1990, 50(14):4177-4189.
146. Lewis J.S., Meeke K., Osipo C., Ross E.A., Kidawi N., Li T., et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Journal of the National Cancer Institute 2005, 97(23):1746-1759.
147. Lewis-Wambi J.S., Kim H.R., Wambi C., Patel R., Pyle J.R., Klein-Szanto A.J., et al. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Research 2008, 10(6):R104.
148. Lewis-Wambi J.S., Swaby R., Kim H., Jordan V.C. Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 2009, 114(1-2):33-39.
149. Lindsay R., Gallagher J.C., Kagan R., Pickar J.H., Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertility and Sterility 2009, 92(3):1045-1052.
150. Lippman M.E., Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 1975, 256(5518):592-593.
151. Lonning P.E. Additive endocrine therapy for advanced breast cancer-Back to the future. Acta Oncologica 2009, 48(8):1092-1101.
152. Lonning P.E., Taylor P.D., Anker G., Iddon J., Wie L., Jorgensen L.M., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment 2001, 67(2):111-116.
153. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. The New England Journal of Medicine 1992, 326(13):852-856.
154. Love R.R., Newcomb P.A., Wiebe D.A., Surawicz T.S., Jordan V.C., Carbone P.P., et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. Journal of the National Cancer Institute 1990, 82(16):1327-1332.
155. Love R.R., Wiebe D.A., Newcomb P.A., Cameron L., Leventhal H., Jordan V.C., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Annals of Internal Medicine 1991, 115(11):860-864.
156. Lunan C.B., Klopper A. Antioestrogens. A review. Clinical Endocrinology 1975, 4(5):551-572.
157. Madlensky L., Natarajan L., Tchu S., Pu M., Mortimer J., Flatt S.W., et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clinical Pharmacology and Therapeutics 2011, 89(5):718-725.
158. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., et al. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute 2004, 96(23):1751-1761.
159. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. The Journal of Clinical Endocrinology and Metabolism 1995, 80(10):2918-2925.
160. Maximov P., Sengupta S., Lewis-Wambi J.S., Kim H.R., Curpan R.F., Jordan V.C. The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: A hypothesis. Hormonal Molecular Biology and Clinical Investigation 2011, 5(1):27-34.
161. Estrogen receptors in human breast cancer 1975, Raven Press, New York. W.L. McGuire, P.P. Carbone, E.P. Vollmer (Eds.).
162. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. The New England Journal of Medicine 2012, 367(5):435-444.
163. Miller C.P., Collini M.D., Tran B.D., Harris H.A., Kharode Y.P., Marzolf J.T., et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. Journal of Medicinal Chemistry 2001, 44(11):1654-1657.
164. NATO Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. The Lancet 1983, 1(8319):257-261.
165. O'Regan R.M., Gajdos C., Dardes R.C., De Los Reyes A., Park W., Rademaker A.W., et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. Journal of the National Cancer Institute 2002, 94(4):274-283.
166. Osborne C.K., Coronado E.B., Robinson J.P. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. European Journal of Cancer & Clinical Oncology 1987, 23(8):1189-1196.
167. Osborne C.K., Hobbs K., Clark G.M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Research 1985, 45(2):584-590.
168. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. Journal of Clinical Oncology 2002, 20(16):3386-3395.
169. Osipo C., Gajdos C., Liu H., Chen B., Jordan V.C. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. Journal of the National Cancer Institute 2003, 95(21):1597-1608.
170. Payre B., de Medina P., Boubekeur N., Mhamdi L., Bertrand-Michel J., Terce F., et al. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Molecular Cancer Therapeutics 2008, 7(12):3707-3718.
171. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
172. Pink J.J., Jiang S.Y., Fritsch M., Jordan V.C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Research 1995, 55(12):2583-2590.
173. Pinkerton J.V., Pickar J.H., Racketa J., Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric 2012, 15(5):411-418.
174. Poirot M. Four decades of discovery in breast cancer research and treatment-An interview with V. Craig Jordan. The International Journal of Developmental Biology 2011, 55:703-712.
175. Powles T.J., Ashley S., Tidy A., Smith I.E., Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute 2007, 99(4):283-290.
176. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. The Lancet 1998, 352(9122):98-101.
177. Powles T.J., Hardy J.R., Ashley S.E., Farrington G.M., Cosgrove D., Davey J.B., et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. British Journal of Cancer 1989, 60(1):126-131.
178. Prentice R.L., Chlebowski R.T., Stefanick M.L., Manson J.E., Langer R.D., Pettinger M., et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. American Journal of Epidemiology 2008, 167(12):1407-1415.
179. Rae J.M., Drury S., Hayes D.F., Stearns V., Thibert J.N., Haynes B.P., et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. Journal of the National Cancer Institute 2012, 104(6):452-460.
180. Regan M.M., Leyland-Jones B., Bouzyk M., Pagani O., Tang W., Kammler R., et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial. Journal of the National Cancer Institute 2012, 104(6):441-451.
181. Riemsma R., Forbes C.A., Amonkar M.M., Lykopoulos K., Diaz J.R., Kleijnen J., et al. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC). Current Medical Research and Opinion 2012, 28(8):1263-1279.
182. Ries L.A.G., Eisner M.P., Kosary C.L. SEER cancer statistics review, 1973-1998 2001, National Cancer Institute, Bethesda, Maryland.
183. Robinson S.P., Koch R., Jordan V.C. In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. Cancer Research 1988, 48(4):784-787.
184. Robson J.M. Oestrous reactions, including mating, produced by triphenyl ethylene. Nature 1937, 140(3535):196.
185. Robson J.M., Schonberg A., Fahim H.A. Duration of action of natural and synthetic oestrogens. Nature 1938, 142:292-293.
186. Robson J.M., Schonberg A. A new synthetic oestrogen with prolonged action when given orally. Nature 1942, 150(3792):22-23.
187. Roop R.P., Ma C.X. Endocrine resistance in breast cancer: Molecular pathways and rational development of targeted therapies. Future Oncology 2012, 8(3):273-292.
188. Rosati R.L., Da Silva Jardine P., Cameron K.O., Thompson D.D., Ke H.Z., Toler S.M., et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. Journal of Medicinal Chemistry 1998, 41(16):2928-2931.
189. Rose C., Thorpe S.M., Andersen K.W., Pedersen B.V., Mouridsen H.T., Blichert-Toft M., et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. The Lancet 1985, 1(8419):16-19.
190. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002, 288(3):321-333.
191. Rutanen E.M., Heikkinen J., Halonen K., Komi J., Lammintausta R., Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Menopause 2003, 10(5):433-439.
192. Schrek R. Fashions in cancer research. 1959-1960 Year book 1960, 26-39. The Year Book Publishers, Chicago. W.B. Wartman (Ed.).
193. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Journal of the American Medical Association 2009, 302(13):1429-1436.
194. SCTO Adjuvant tamoxifen in the management of operable cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. The Lancet 1987, 2(8852):171-175.
195. Sengupta S., Jordan V.C. Novel selective estrogen receptor modulators. Estrogen actions, SERMs, and women's health 2013, Imperial College Press, London. V.C. Jordan (Ed.).
196. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95(7):927-937.
197. Shim W.S., Conaway M., Masamura S., Yue W., Wang J.P., Kmar R., et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000, 141(1):396-405.
198. Shimkin M.B., Wyman R.S. Effect of adrenalectomy and ovariectomy on mammary carcinogenesis in strain C3H mice. Journal of the National Cancer Institute 1945, 6:187-189.
199. Shimkin M.B., Wyman R.S. Mammary tumors in male mice implanted with estrogen-cholesterol pellets. Journal of the National Cancer Institute 1946, 7(2):71-75.
200. Shimkin M.B., Wyman R.S., Andervont H.B. Mammary tumors in mice following transplantation of mammary tissue. Journal of the National Cancer Institute 1946, 7(2):77.
201. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association 2003, 289(20):2651-2662.
202. Silverman S.L., Chines A.A., Kendler D.L., Kung A.W., Teglbjaerg C.S., Felsenberg D., et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study. Osteoporosis International 2012, 23(1):351-363.
203. Song R.X., Mor G., Naftolin F., McPherson R.A., Song J., Zhang Z., et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. Journal of the National Cancer Institute 2001, 93(22):1714-1723.
204. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(14):8418-8423.
205. Speroff L. A good man, Gregory Goodwin Pincus: The man, his story, the birth control pill 2009, Arnica Publishing, Portland, Oregon.
206. Stein R.C., Dowsett M., Cunningham D.C., Davenport J., Ford H.T., Gazet J.C., et al. Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. British Journal of Cancer 1990, 61(3):451-453.
207. Stoll B. Breast cancer management early and late 1977, William Herman Medical Books Ltd, London.
208. Stoll B.A. Palliation by castration or by hormone administration. Breast cancer management early and late 1977, 133-146. W. Heinemann Medical Books Ltd, London. B.A. Stoll (Ed.).
209. Sutherland R.L., Murphy L.C., San Foo M., Green M.D., Whybourne A.M., Krozowski Z.S. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 1980, 288(5788):273-275.
210. Sweeney E.E., McDaniel R.E., Maximov P.Y., Fan P., Jordan V.C. Models and mechanisms of acquired antihormone resistance in breast cancer: Significant clinical progress despite limitations. Hormonal Molecular Biology and Clinical Investigation 2012, 9(2):143-163.
211. Thompson C.R., Werner H.W. Fat storage of an estrogen in women following orally administered tri-p-anisyl chloroethylene. Proceedings of the Society for Experimental Biology and Medicine 1953, 84:491-492.
212. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine 2005, 353(26):2747-2757.
213. Toft D., Gorski J. A receptor molecule for estrogens: Isolation from the rat uterus and preliminary characterization. PNAS 1966, 55(6):1574-1581.
214. Toft D., Shyamala G., Gorski J. A receptor molecule for estrogens: Studies using a cell-free system. Proceedings of the National Academy of Sciences of the United States of America 1967, 57(6):1740-1743.
215. Turner R.T., Evans G.L., Sluka J.P., Adrian M.D., Bryant H.U., Turner C.H., et al. Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology 1998, 139(9):3712-3720.
216. Turner R.T., Evans G.L., Wakley G.K. Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: Inhibition of indices of formation and resorption. Journal of Bone and Mineral Research 1993, 8(3):359-366.
217. Turner R.T., Wakley G.K., Hannon K.S., Bell N.H. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. Journal of Bone and Mineral Research 1987, 2(5):449-456.
218. Turner R.T., Wakley G.K., Hannon K.S., Bell N.H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988, 122(3):1146-1150.
219. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. The Lancet 1998, 352(9122):93-97.
220. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Journal of the American Medical Association 2006, 295(23):2727-2741.
221. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prevention Research (Philadelphia, Pa.) 2010, 3(6):696-706.
222. Voipio S.K., Komi J., Kangas L., Halonen K., DeGregorio M.W., Erkkola R.U. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002, 43(3):207-214.
223. Wallace O.B., Lauwers K.S., Dodge J.A., May S.A., Calvin J.R., Hinklin R., et al. A selective estrogen receptor modulator for the treatment of hot flushes. Journal of Medicinal Chemistry 2006, 49(3):843-846.
224. Walpole A.L., Paterson E. Synthetic oestrogens in mammary cancer. The Lancet 1949, 2(6583):783-786.
225. Watanabe N., Ikeno A., Minato H., Nakagawa H., Kohayakawa C., Tsuji J. Discovery and preclinical characterization of (+)-3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1'-indane]-5,5'-diol hydrochloride: A promising nonsteroidal estrogen receptor agonist for hot flush. Journal of Medicinal Chemistry 2003, 46(19):3961-3964.
226. Welsch C.W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Research 1985, 45(8):3415-3443.
227. Welshons W.V., Jordan V.C. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. European Journal of Cancer & Clinical Oncology 1987, 23(12):1935-1939.
228. Wolf D.M., Jordan V.C. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results in Cancer Research 1993, 127:23-33.
229. Yang L., Parkin D., Ferlay J., Li L., Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiology, Biomarkers & Prevention 2005, 14(1):243-249.
230. Yao K., Lee E.S., Bentrem D.J., England G., Schafer J.I., O'Regan R.M., et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research 2000, 6(5):2028-2036.